Skip to main content

Week in Review: Nikang Raises $200 Million from US and China Investors

Deals and Financings   NiKang Therapeutics, a Delaware  biotech incubated by CBC Group, raised $200 million in a Series C financing from US and  China  investors; Esco Lifesciences of  Singapore closed an over-subscribed $200 million Series A and crossover round to expand its life sciences tool business, especially in China ;  Trials and Approvals   Suzhou CStone Pharma said its anti-PD-L1 mAb met its primary progression-free endpoint in a Phase III trial in patients with stage III NSCLC; Shanghai AffaMed Therapeutics was approved to start a China Phase IIb trial of its Parkinson's Disease candidate; Suzhou Innovent began a China Phase III trial of pemigatinib, a FGFR 1/2/3 inhibitor, in patients with cholangiocarcinoma; Transcenta of Suzhou reported positive results from a Phase I trial of its pH-dependent PD-L1 antibody in pre-treated solid tumor and lymphoma patients; Shanghai's Sinovant reported positive topline results from its Phase III bridging study of lefamulin for community acquired bacterial pneumonia; TransThera, a clinical stage  Nanjing  biopharma, will partner with Roche to test a combination therapy for  China  patients with gastrointestinal tract cancers; Hangzhou 's Ascletis Pharma reported that  China  has accepted for review the company's filing for a clinical trial of a brain cancer treatment; HitGen of Chengdu will collaborate with Dorian to discover senoblockers, which fight aging by rejuvenating cells and tissues; Korea 's Hyundai Bio said its niclosamide oral treatment for COVID-19 increased the sustained bioavailablity of the API.  Stock Symbol: (HK: 2616) (HK: 01801) (HK: 1672) (SHA: 688222) (KOSDAQ: 048410)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.